pharmacist’s letter : prescriber’s letter
TRANSCRIPT
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 16
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 26
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Generation Organisms Covered12
Fourth
Generationbull Broad coverage of gram positive and gram negative organisms
Coverage of Pseudomonas similar to ceftazidime Coverage of S
pneumonia similar to ceftriaxone
bull Some anaerobic coverage No coverage of B fragilis
bullNo oral agents curr
bullLess susceptible to
lactamases than sec
better against Citrob
FifthGeneration
(MRSA-
active)
bull Enhanced coverage of gram positive organisms MRSA S pneumonia and E faecalis
bull Similar gram negative coverage to third- and fourth-generation agents
Ceftaroline does not cover Pseudomonas
bull Limited anaerobic activity
bullNo oral agents curr
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available First Generation Agents
Cefadroxil( Duricef ) PO Y(ge6 weeks
depending on
indication
[Canada])
Y(CrCL le50 mLmin) N Ybull
bull
su
Cefazolin( Ancef
Kefzol-US)
IMIV Y Y
(CrCl lt55 mLmin)
N Y bull A
Cephalexin
(Keflex)
PO Y Y
(Some sourcesrecommend dose
reduction with CrCL
lt40 to 50 mLmin)34
N Y bull
su D
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 36
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Second Generation Agents
Cefaclor(Ceclor )
PO Y
(ge1 month
[US])
N N Y bull
U
bull
su
(U
Cefotetan-
US only
(Cefotan)
IV N Y
(CrCl le30 mLmin)
N Y bull
Cefoxitin( Mefoxin)
IMIV Y
(gt3months
[US])
Y
(CrCl le50 mLmin)
N Y bull
C
Cefprozil(Cefzil)
PO Y
(ge6 months)
Y
(CrCl
le30 mLmin
[Canada]
lt30 mLmin [US])
N Y bull
U
bull
su
Cefuroxime(Ceftin [oral]
Zinacef
[injectable])
POIMIV Y
(ge3 months
[oral])
(gt3 months
[InjectableUS]
Y
(CrCl le20 mLmin
[for injectable] no
data for oral route)
N Y bull
C
bull
p
ta
bull
in
la
bull
c
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 46
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Third Generation Agents
Cefdinir-US
only
(Omnicef )
PO Y
(ge6 months)
Y
(CrCl lt30 mLmin)
N Y bull
bull
suCefditorenpivoxil-US
only
(Spectracef )
PO N
(ge12 years)
Y(CrCl lt50 mLmin)
N Y bull
Cefixime(Suprax)
PO Y
(ge6 months)
Y
(CrCl lt40 mLmin
[Canada]
lt60 mLmin [US])
N N bull
su
Cefotaxime(Claforan)
IMIV Y Y
(CrCl lt20 mLmin)
N Y bull
Cefpodoxime
proxetil-USonly
(Vantin)
PO Y
(ge2 months)
Y
(CrCl lt30mLmin)
N Y bull
su
Ceftazidime(Fortaz)
IMIV Y Y
(CrCl le50 mLmin
[Canada]
lt50 mLmin [US])
N Y bull
Ceftibuten-
US only
(Cedax)
PO Y
(ge6 months)
Y
(CrCl lt50 mLmin)
N N bull
su
Ceftriaxone( Rocephin)
IMIV Y
(gt28 days)
N N Y bull
C
Fourth Generation
Cefipime ( Maxipime)
IMIV Y
(ge2 months)
Y
(CrCl le50 mLmin
[Canada]
le60 mLmin [US])
N Y bull
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 56
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Fifth Generation (MRSA-active)
Ceftaroline-US only
(Teflaro)
IV N Y
(CrCl le50 mLmin)
N N bull
a Off-label routes such as intraperitoneal may be appropriate for some drugs
b Consult a neonatal dosing reference such as Neofax for information on use in premature neonates
US product information used for preparation of the above chart cefadroxil (Ranbaxy July 2007) cefazolin(October 2010) cefaclor (Ranbaxy May 2007) cefotetan (B Braun May 2011) Mefoxin (October 2006) cefproz
(August 2010) Ceftin (January 2010) cefdinir (Teva June 2009) Spectracef (2011) Suprax (October 2008) Claf
2007) Fortaz (August 2010) Cedax (April 2010) Rocephin (November 2010) Maxipime (August 2010) Teflaro
Canadian product monographs used for preparation of the above chart cefadroxil (Teva March 2012) cefa(May 2012) Ceclor (February 2012) cefoxitin (Hospira August 2010) Cefzil (December 2010) Ceftin (Novemb
(Pharmaceutical Partners of Canada January 2008) Suprax (November 2010) Claforan (November 2010) Forta
(Novopharm February 2012) Maxipime (September 2008)
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary o
clinical judgments based on the content of this document Our editors have researched the information with input from exp
organizations Information and internet links in this article were current as of the date of publication
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 66
(PL Detail-Document 280706 Page 6 of 6)
Project Leader in preparation of this PL Detail- Document Stacy A Hester RPh BCPS
Assistant Editor
References1 Andes DR Craig WA Cephalosporins In Mandell
GL Bennett JE Dolin R Eds Principles andPractice of Infectious Diseases 7
th ed Philadelphia
PA Churchill Livngstone Elsevier 20092 Chambers HF Eliopoulos GM Gilbert DN et al The
Sanford Guide to Antimicrobial Therapy WebEdition Sperryville VA Antimicrobial Therapy Inc2012 httpwebeditionsanfordguidecom(Accessed June 14 2012)
3 Clinical Pharmacology [database online] TampaFL Cold Standard Inc 2012httpwwwclinicalpharmacologycom (AccessedOctober 1 2012)
4 Lexicomp Online Hudson OH Lexi-Comp Inchttponlinelexicom (Accessed October 1 2012)
Cite this document as follows PL Detail-Document Comparison of Cephalosporins Pharmacistrsquos
LetterPrescriberrsquos Letter July 2012
Evidence and Recommendations You Can Trusthellip
3120 West March Lane PO Box 8190 Stockton CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249Copyright 983209 2012 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents like this oneon any topic covered in any issue by going to wwwpharmacistslettercomwwwprescriberslettercom or wwwpharmacytechnicianslettercom
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 26
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Generation Organisms Covered12
Fourth
Generationbull Broad coverage of gram positive and gram negative organisms
Coverage of Pseudomonas similar to ceftazidime Coverage of S
pneumonia similar to ceftriaxone
bull Some anaerobic coverage No coverage of B fragilis
bullNo oral agents curr
bullLess susceptible to
lactamases than sec
better against Citrob
FifthGeneration
(MRSA-
active)
bull Enhanced coverage of gram positive organisms MRSA S pneumonia and E faecalis
bull Similar gram negative coverage to third- and fourth-generation agents
Ceftaroline does not cover Pseudomonas
bull Limited anaerobic activity
bullNo oral agents curr
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available First Generation Agents
Cefadroxil( Duricef ) PO Y(ge6 weeks
depending on
indication
[Canada])
Y(CrCL le50 mLmin) N Ybull
bull
su
Cefazolin( Ancef
Kefzol-US)
IMIV Y Y
(CrCl lt55 mLmin)
N Y bull A
Cephalexin
(Keflex)
PO Y Y
(Some sourcesrecommend dose
reduction with CrCL
lt40 to 50 mLmin)34
N Y bull
su D
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 36
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Second Generation Agents
Cefaclor(Ceclor )
PO Y
(ge1 month
[US])
N N Y bull
U
bull
su
(U
Cefotetan-
US only
(Cefotan)
IV N Y
(CrCl le30 mLmin)
N Y bull
Cefoxitin( Mefoxin)
IMIV Y
(gt3months
[US])
Y
(CrCl le50 mLmin)
N Y bull
C
Cefprozil(Cefzil)
PO Y
(ge6 months)
Y
(CrCl
le30 mLmin
[Canada]
lt30 mLmin [US])
N Y bull
U
bull
su
Cefuroxime(Ceftin [oral]
Zinacef
[injectable])
POIMIV Y
(ge3 months
[oral])
(gt3 months
[InjectableUS]
Y
(CrCl le20 mLmin
[for injectable] no
data for oral route)
N Y bull
C
bull
p
ta
bull
in
la
bull
c
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 46
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Third Generation Agents
Cefdinir-US
only
(Omnicef )
PO Y
(ge6 months)
Y
(CrCl lt30 mLmin)
N Y bull
bull
suCefditorenpivoxil-US
only
(Spectracef )
PO N
(ge12 years)
Y(CrCl lt50 mLmin)
N Y bull
Cefixime(Suprax)
PO Y
(ge6 months)
Y
(CrCl lt40 mLmin
[Canada]
lt60 mLmin [US])
N N bull
su
Cefotaxime(Claforan)
IMIV Y Y
(CrCl lt20 mLmin)
N Y bull
Cefpodoxime
proxetil-USonly
(Vantin)
PO Y
(ge2 months)
Y
(CrCl lt30mLmin)
N Y bull
su
Ceftazidime(Fortaz)
IMIV Y Y
(CrCl le50 mLmin
[Canada]
lt50 mLmin [US])
N Y bull
Ceftibuten-
US only
(Cedax)
PO Y
(ge6 months)
Y
(CrCl lt50 mLmin)
N N bull
su
Ceftriaxone( Rocephin)
IMIV Y
(gt28 days)
N N Y bull
C
Fourth Generation
Cefipime ( Maxipime)
IMIV Y
(ge2 months)
Y
(CrCl le50 mLmin
[Canada]
le60 mLmin [US])
N Y bull
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 56
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Fifth Generation (MRSA-active)
Ceftaroline-US only
(Teflaro)
IV N Y
(CrCl le50 mLmin)
N N bull
a Off-label routes such as intraperitoneal may be appropriate for some drugs
b Consult a neonatal dosing reference such as Neofax for information on use in premature neonates
US product information used for preparation of the above chart cefadroxil (Ranbaxy July 2007) cefazolin(October 2010) cefaclor (Ranbaxy May 2007) cefotetan (B Braun May 2011) Mefoxin (October 2006) cefproz
(August 2010) Ceftin (January 2010) cefdinir (Teva June 2009) Spectracef (2011) Suprax (October 2008) Claf
2007) Fortaz (August 2010) Cedax (April 2010) Rocephin (November 2010) Maxipime (August 2010) Teflaro
Canadian product monographs used for preparation of the above chart cefadroxil (Teva March 2012) cefa(May 2012) Ceclor (February 2012) cefoxitin (Hospira August 2010) Cefzil (December 2010) Ceftin (Novemb
(Pharmaceutical Partners of Canada January 2008) Suprax (November 2010) Claforan (November 2010) Forta
(Novopharm February 2012) Maxipime (September 2008)
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary o
clinical judgments based on the content of this document Our editors have researched the information with input from exp
organizations Information and internet links in this article were current as of the date of publication
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 66
(PL Detail-Document 280706 Page 6 of 6)
Project Leader in preparation of this PL Detail- Document Stacy A Hester RPh BCPS
Assistant Editor
References1 Andes DR Craig WA Cephalosporins In Mandell
GL Bennett JE Dolin R Eds Principles andPractice of Infectious Diseases 7
th ed Philadelphia
PA Churchill Livngstone Elsevier 20092 Chambers HF Eliopoulos GM Gilbert DN et al The
Sanford Guide to Antimicrobial Therapy WebEdition Sperryville VA Antimicrobial Therapy Inc2012 httpwebeditionsanfordguidecom(Accessed June 14 2012)
3 Clinical Pharmacology [database online] TampaFL Cold Standard Inc 2012httpwwwclinicalpharmacologycom (AccessedOctober 1 2012)
4 Lexicomp Online Hudson OH Lexi-Comp Inchttponlinelexicom (Accessed October 1 2012)
Cite this document as follows PL Detail-Document Comparison of Cephalosporins Pharmacistrsquos
LetterPrescriberrsquos Letter July 2012
Evidence and Recommendations You Can Trusthellip
3120 West March Lane PO Box 8190 Stockton CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249Copyright 983209 2012 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents like this oneon any topic covered in any issue by going to wwwpharmacistslettercomwwwprescriberslettercom or wwwpharmacytechnicianslettercom
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 36
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Second Generation Agents
Cefaclor(Ceclor )
PO Y
(ge1 month
[US])
N N Y bull
U
bull
su
(U
Cefotetan-
US only
(Cefotan)
IV N Y
(CrCl le30 mLmin)
N Y bull
Cefoxitin( Mefoxin)
IMIV Y
(gt3months
[US])
Y
(CrCl le50 mLmin)
N Y bull
C
Cefprozil(Cefzil)
PO Y
(ge6 months)
Y
(CrCl
le30 mLmin
[Canada]
lt30 mLmin [US])
N Y bull
U
bull
su
Cefuroxime(Ceftin [oral]
Zinacef
[injectable])
POIMIV Y
(ge3 months
[oral])
(gt3 months
[InjectableUS]
Y
(CrCl le20 mLmin
[for injectable] no
data for oral route)
N Y bull
C
bull
p
ta
bull
in
la
bull
c
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 46
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Third Generation Agents
Cefdinir-US
only
(Omnicef )
PO Y
(ge6 months)
Y
(CrCl lt30 mLmin)
N Y bull
bull
suCefditorenpivoxil-US
only
(Spectracef )
PO N
(ge12 years)
Y(CrCl lt50 mLmin)
N Y bull
Cefixime(Suprax)
PO Y
(ge6 months)
Y
(CrCl lt40 mLmin
[Canada]
lt60 mLmin [US])
N N bull
su
Cefotaxime(Claforan)
IMIV Y Y
(CrCl lt20 mLmin)
N Y bull
Cefpodoxime
proxetil-USonly
(Vantin)
PO Y
(ge2 months)
Y
(CrCl lt30mLmin)
N Y bull
su
Ceftazidime(Fortaz)
IMIV Y Y
(CrCl le50 mLmin
[Canada]
lt50 mLmin [US])
N Y bull
Ceftibuten-
US only
(Cedax)
PO Y
(ge6 months)
Y
(CrCl lt50 mLmin)
N N bull
su
Ceftriaxone( Rocephin)
IMIV Y
(gt28 days)
N N Y bull
C
Fourth Generation
Cefipime ( Maxipime)
IMIV Y
(ge2 months)
Y
(CrCl le50 mLmin
[Canada]
le60 mLmin [US])
N Y bull
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 56
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Fifth Generation (MRSA-active)
Ceftaroline-US only
(Teflaro)
IV N Y
(CrCl le50 mLmin)
N N bull
a Off-label routes such as intraperitoneal may be appropriate for some drugs
b Consult a neonatal dosing reference such as Neofax for information on use in premature neonates
US product information used for preparation of the above chart cefadroxil (Ranbaxy July 2007) cefazolin(October 2010) cefaclor (Ranbaxy May 2007) cefotetan (B Braun May 2011) Mefoxin (October 2006) cefproz
(August 2010) Ceftin (January 2010) cefdinir (Teva June 2009) Spectracef (2011) Suprax (October 2008) Claf
2007) Fortaz (August 2010) Cedax (April 2010) Rocephin (November 2010) Maxipime (August 2010) Teflaro
Canadian product monographs used for preparation of the above chart cefadroxil (Teva March 2012) cefa(May 2012) Ceclor (February 2012) cefoxitin (Hospira August 2010) Cefzil (December 2010) Ceftin (Novemb
(Pharmaceutical Partners of Canada January 2008) Suprax (November 2010) Claforan (November 2010) Forta
(Novopharm February 2012) Maxipime (September 2008)
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary o
clinical judgments based on the content of this document Our editors have researched the information with input from exp
organizations Information and internet links in this article were current as of the date of publication
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 66
(PL Detail-Document 280706 Page 6 of 6)
Project Leader in preparation of this PL Detail- Document Stacy A Hester RPh BCPS
Assistant Editor
References1 Andes DR Craig WA Cephalosporins In Mandell
GL Bennett JE Dolin R Eds Principles andPractice of Infectious Diseases 7
th ed Philadelphia
PA Churchill Livngstone Elsevier 20092 Chambers HF Eliopoulos GM Gilbert DN et al The
Sanford Guide to Antimicrobial Therapy WebEdition Sperryville VA Antimicrobial Therapy Inc2012 httpwebeditionsanfordguidecom(Accessed June 14 2012)
3 Clinical Pharmacology [database online] TampaFL Cold Standard Inc 2012httpwwwclinicalpharmacologycom (AccessedOctober 1 2012)
4 Lexicomp Online Hudson OH Lexi-Comp Inchttponlinelexicom (Accessed October 1 2012)
Cite this document as follows PL Detail-Document Comparison of Cephalosporins Pharmacistrsquos
LetterPrescriberrsquos Letter July 2012
Evidence and Recommendations You Can Trusthellip
3120 West March Lane PO Box 8190 Stockton CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249Copyright 983209 2012 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents like this oneon any topic covered in any issue by going to wwwpharmacistslettercomwwwprescriberslettercom or wwwpharmacytechnicianslettercom
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 46
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Third Generation Agents
Cefdinir-US
only
(Omnicef )
PO Y
(ge6 months)
Y
(CrCl lt30 mLmin)
N Y bull
bull
suCefditorenpivoxil-US
only
(Spectracef )
PO N
(ge12 years)
Y(CrCl lt50 mLmin)
N Y bull
Cefixime(Suprax)
PO Y
(ge6 months)
Y
(CrCl lt40 mLmin
[Canada]
lt60 mLmin [US])
N N bull
su
Cefotaxime(Claforan)
IMIV Y Y
(CrCl lt20 mLmin)
N Y bull
Cefpodoxime
proxetil-USonly
(Vantin)
PO Y
(ge2 months)
Y
(CrCl lt30mLmin)
N Y bull
su
Ceftazidime(Fortaz)
IMIV Y Y
(CrCl le50 mLmin
[Canada]
lt50 mLmin [US])
N Y bull
Ceftibuten-
US only
(Cedax)
PO Y
(ge6 months)
Y
(CrCl lt50 mLmin)
N N bull
su
Ceftriaxone( Rocephin)
IMIV Y
(gt28 days)
N N Y bull
C
Fourth Generation
Cefipime ( Maxipime)
IMIV Y
(ge2 months)
Y
(CrCl le50 mLmin
[Canada]
le60 mLmin [US])
N Y bull
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 56
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Fifth Generation (MRSA-active)
Ceftaroline-US only
(Teflaro)
IV N Y
(CrCl le50 mLmin)
N N bull
a Off-label routes such as intraperitoneal may be appropriate for some drugs
b Consult a neonatal dosing reference such as Neofax for information on use in premature neonates
US product information used for preparation of the above chart cefadroxil (Ranbaxy July 2007) cefazolin(October 2010) cefaclor (Ranbaxy May 2007) cefotetan (B Braun May 2011) Mefoxin (October 2006) cefproz
(August 2010) Ceftin (January 2010) cefdinir (Teva June 2009) Spectracef (2011) Suprax (October 2008) Claf
2007) Fortaz (August 2010) Cedax (April 2010) Rocephin (November 2010) Maxipime (August 2010) Teflaro
Canadian product monographs used for preparation of the above chart cefadroxil (Teva March 2012) cefa(May 2012) Ceclor (February 2012) cefoxitin (Hospira August 2010) Cefzil (December 2010) Ceftin (Novemb
(Pharmaceutical Partners of Canada January 2008) Suprax (November 2010) Claforan (November 2010) Forta
(Novopharm February 2012) Maxipime (September 2008)
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary o
clinical judgments based on the content of this document Our editors have researched the information with input from exp
organizations Information and internet links in this article were current as of the date of publication
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 66
(PL Detail-Document 280706 Page 6 of 6)
Project Leader in preparation of this PL Detail- Document Stacy A Hester RPh BCPS
Assistant Editor
References1 Andes DR Craig WA Cephalosporins In Mandell
GL Bennett JE Dolin R Eds Principles andPractice of Infectious Diseases 7
th ed Philadelphia
PA Churchill Livngstone Elsevier 20092 Chambers HF Eliopoulos GM Gilbert DN et al The
Sanford Guide to Antimicrobial Therapy WebEdition Sperryville VA Antimicrobial Therapy Inc2012 httpwebeditionsanfordguidecom(Accessed June 14 2012)
3 Clinical Pharmacology [database online] TampaFL Cold Standard Inc 2012httpwwwclinicalpharmacologycom (AccessedOctober 1 2012)
4 Lexicomp Online Hudson OH Lexi-Comp Inchttponlinelexicom (Accessed October 1 2012)
Cite this document as follows PL Detail-Document Comparison of Cephalosporins Pharmacistrsquos
LetterPrescriberrsquos Letter July 2012
Evidence and Recommendations You Can Trusthellip
3120 West March Lane PO Box 8190 Stockton CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249Copyright 983209 2012 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents like this oneon any topic covered in any issue by going to wwwpharmacistslettercomwwwprescriberslettercom or wwwpharmacytechnicianslettercom
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 56
(P
Copyright copy 2012 by Therapeutic Research CenterPO Box 8190 Stockton CA 95208 ~ Phone 209-472-2240 ~ Fax 209-472-2249
wwwpharmacistslettercom ~ wwwprescriberslettercom ~ wwwpharmacytechnicianslettercom
Drug Routea Approved in
Childrenb
Renal Dose
Adjustment
Hepatic Dose
Adjustment
Generic
Available
Fifth Generation (MRSA-active)
Ceftaroline-US only
(Teflaro)
IV N Y
(CrCl le50 mLmin)
N N bull
a Off-label routes such as intraperitoneal may be appropriate for some drugs
b Consult a neonatal dosing reference such as Neofax for information on use in premature neonates
US product information used for preparation of the above chart cefadroxil (Ranbaxy July 2007) cefazolin(October 2010) cefaclor (Ranbaxy May 2007) cefotetan (B Braun May 2011) Mefoxin (October 2006) cefproz
(August 2010) Ceftin (January 2010) cefdinir (Teva June 2009) Spectracef (2011) Suprax (October 2008) Claf
2007) Fortaz (August 2010) Cedax (April 2010) Rocephin (November 2010) Maxipime (August 2010) Teflaro
Canadian product monographs used for preparation of the above chart cefadroxil (Teva March 2012) cefa(May 2012) Ceclor (February 2012) cefoxitin (Hospira August 2010) Cefzil (December 2010) Ceftin (Novemb
(Pharmaceutical Partners of Canada January 2008) Suprax (November 2010) Claforan (November 2010) Forta
(Novopharm February 2012) Maxipime (September 2008)
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary o
clinical judgments based on the content of this document Our editors have researched the information with input from exp
organizations Information and internet links in this article were current as of the date of publication
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 66
(PL Detail-Document 280706 Page 6 of 6)
Project Leader in preparation of this PL Detail- Document Stacy A Hester RPh BCPS
Assistant Editor
References1 Andes DR Craig WA Cephalosporins In Mandell
GL Bennett JE Dolin R Eds Principles andPractice of Infectious Diseases 7
th ed Philadelphia
PA Churchill Livngstone Elsevier 20092 Chambers HF Eliopoulos GM Gilbert DN et al The
Sanford Guide to Antimicrobial Therapy WebEdition Sperryville VA Antimicrobial Therapy Inc2012 httpwebeditionsanfordguidecom(Accessed June 14 2012)
3 Clinical Pharmacology [database online] TampaFL Cold Standard Inc 2012httpwwwclinicalpharmacologycom (AccessedOctober 1 2012)
4 Lexicomp Online Hudson OH Lexi-Comp Inchttponlinelexicom (Accessed October 1 2012)
Cite this document as follows PL Detail-Document Comparison of Cephalosporins Pharmacistrsquos
LetterPrescriberrsquos Letter July 2012
Evidence and Recommendations You Can Trusthellip
3120 West March Lane PO Box 8190 Stockton CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249Copyright 983209 2012 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents like this oneon any topic covered in any issue by going to wwwpharmacistslettercomwwwprescriberslettercom or wwwpharmacytechnicianslettercom
8202019 Pharmacistrsquos Letter Prescriberrsquos Letter
httpslidepdfcomreaderfullpharmacists-letter-prescribers-letter 66
(PL Detail-Document 280706 Page 6 of 6)
Project Leader in preparation of this PL Detail- Document Stacy A Hester RPh BCPS
Assistant Editor
References1 Andes DR Craig WA Cephalosporins In Mandell
GL Bennett JE Dolin R Eds Principles andPractice of Infectious Diseases 7
th ed Philadelphia
PA Churchill Livngstone Elsevier 20092 Chambers HF Eliopoulos GM Gilbert DN et al The
Sanford Guide to Antimicrobial Therapy WebEdition Sperryville VA Antimicrobial Therapy Inc2012 httpwebeditionsanfordguidecom(Accessed June 14 2012)
3 Clinical Pharmacology [database online] TampaFL Cold Standard Inc 2012httpwwwclinicalpharmacologycom (AccessedOctober 1 2012)
4 Lexicomp Online Hudson OH Lexi-Comp Inchttponlinelexicom (Accessed October 1 2012)
Cite this document as follows PL Detail-Document Comparison of Cephalosporins Pharmacistrsquos
LetterPrescriberrsquos Letter July 2012
Evidence and Recommendations You Can Trusthellip
3120 West March Lane PO Box 8190 Stockton CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249Copyright 983209 2012 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents like this oneon any topic covered in any issue by going to wwwpharmacistslettercomwwwprescriberslettercom or wwwpharmacytechnicianslettercom